WuXi Biologics (Cayman)MEX:2269N 99 Interest Coverage is 68.49 as of Dec. 2025, which is 51% above its 10-year median of 45.28. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, WuXi Biologics (Cayman) ranks worse than 57.03% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. WuXi Biologics (Cayman)'s
Operating Income
for the
six
months ended in Dec. 2025 was MXN10,421 Mil. WuXi Biologics (Cayman)'s Interest Expense for the
six
months ended in Dec. 2025 was MXN-152 Mil.
WuXi Biologics (Cayman)'s interest coverage for the quarter that ended in Dec. 2025 was 68.49.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Interest Coverage or its related term are showing as below:
MEX:2269N'
s Interest Coverage Range Over the Past 10 Years
Min: 9.41 Med: 45.28 Max: No Debt
Current: 49.41
MEX:2269N's Interest Coverage is ranked worse than 57.03% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs MEX:2269N: 49.41
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
WuXi Biologics (Cayman) Interest Coverage Related Terms
WuXi Biologics (Cayman) Interest Coverage Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:2269N vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Interest Coverage distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a Interest Coverage of 68.49 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on WuXi Biologics (Cayman) and its competitors. This is 51% above median its historical median of 45.28. Over the past decade, WuXi Biologics (Cayman)'s Interest Coverage has ranged from 9.41 to 10,000.00. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #215 out of 377 companies in the Biotechnology industry, placing it in the top 57%.
Is WuXi Biologics (Cayman)'s Interest Coverage too high?
WuXi Biologics (Cayman)'s current Interest Coverage of 68.49 is 51% above median its 10-year median of 45.28. Over the past 10 years, this metric has ranged from a low of 9.41 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. WuXi Biologics (Cayman)'s value of 68.49 is 35.4% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #215 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #215 out of 377 companies for Interest Coverage. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Interest Coverage is 106.07. WuXi Biologics (Cayman)'s value of 68.49 is 35.4% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Interest Coverage has ranged from 9.41 to 10,000.00 over the past decade. While the company's 10-year median is 45.28 vs. the industry median of 106.07, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Interest Coverage of 68.49 is 35.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Interest Coverage is 68.49, which is 51% above median its own 10-year median of 45.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Interest Coverage of 68.49. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Interest Coverage is 68.49, which is 51% above median its 10-year median of 45.28 and 35.4% below the Biotechnology industry median of 106.07. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Interest Coverage is 68.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Interest Coverage: 68.49 (51% above median its 10-year median of 45.28)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
Industry Position: 35.4% below the Biotechnology median (#215 of 377)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
